跳至主要内容
临床试验/2023-509258-71-00
2023-509258-71-00招募中1 期

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL

Janssen Cilag International4 个研究点 分布在 2 个国家目标入组 30 人开始时间: 2024年7月3日最近更新:

试验速览

阶段
1 期
状态
招募中
入组人数
30
试验地点
4

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

CTIS Point of Contact

Scientific

Janssen Cilag International

研究点 (4)

Loading locations...

相似试验

进行中(未招募)
1 期
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
CTIS2023-504403-92-00Janssen - Cilag International200
尚未招募
不适用
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myelomamultiple myeloma
NL-OMON53500Janssen-Cilag12
已完成
不适用
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndromebloodcancer10024324Acute Myeloid Leukemia
NL-OMON55771MacroGenics Inc.20
进行中(未招募)
1 期
A Phase 1/2 Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeRelapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003813-11-DEMacroGenics, Inc.330
进行中(未招募)
1 期
A Phase 1/2 Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeRelapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003813-11-GBMacroGenics, Inc.330